Amato M, Hüppi P, Markus D
Department of Obstetrics and Gynecology, University of Berne, Switzerland.
J Perinatol. 1993 Jan-Feb;13(1):2-7.
Some trials in premature infants with respiratory distress syndrome have shown an increased incidence of patent ductus arteriosus after exogenous surfactant therapy. The effect of prophylactic ethamsylate on patent ductus arteriosus after intratracheal administration of a single dose of porcine surfactant preparation (Curosurf, 2.5 ml/kg) was studied in a group of 20 preterm infants with severe respiratory distress syndrome. Gestational age of the patients was 29.2 +/- 2.5 weeks (mean +/- SD), and birth weight was 1158 +/- 319 gm. Ethamsylate (12.5 mg/kg) was given prophylactically within the first 4 hours of life followed by 6-hourly doses for 4 days. Hemodynamically significant patent ductus arteriosus occurred more frequently in the untreated group (8 of 10) than in the ethamsylate group (2 of 10) (p < 0.02). No acute adverse effects were attributed to the therapy. This preliminary experience suggests that ethamsylate, an inhibitor of prostaglandin biosynthesis, could be useful in reducing the incidence of patent ductus arteriosus in very low birth weight infants treated with exogenous surfactant.
一些针对患有呼吸窘迫综合征的早产儿的试验表明，外源性表面活性剂治疗后动脉导管未闭的发生率有所增加。在一组20名患有严重呼吸窘迫综合征的早产儿中，研究了预防性使用酚磺乙胺对气管内给予单剂量猪表面活性剂制剂（固尔苏，2.5 ml/kg）后动脉导管未闭的影响。患者的胎龄为29.2±2.5周（均值±标准差），出生体重为1158±319克。在出生后的头4小时内预防性给予酚磺乙胺（12.5 mg/kg），随后每6小时给药一次，持续4天。未治疗组（10例中有8例）血流动力学显著的动脉导管未闭发生率高于酚磺乙胺组（10例中有2例）（p<0.02）。该治疗未发现急性不良反应。这一初步经验表明，酚磺乙胺作为一种前列腺素生物合成抑制剂，可能有助于降低接受外源性表面活性剂治疗的极低出生体重儿动脉导管未闭的发生率。
